Optimizing Toxicity Management for CDK4/6 Inhibitors in HR Positive Breast Cancer

This segment focuses on evidence based strategies to manage class specific toxicities of CDK4/6 inhibitors while preserving adherence and therapeutic benefit in HR positive HER2 negative breast cancer. The panel emphasizes that proactive education and anticipatory guidance are central to minimizing early treatment disruptions. Clinicians should outline expected timelines for cytopenias, liver enzyme elevations and GI effects to help patients understand when monitoring is most critical. Structured lab schedules, ECG monitoring for agents associated with QTc prolongation, and individualized calendars created with nursing teams support timely assessments and dose adjustments. Experts highlight growing data showing that dose reductions of abemaciclib do not compromise efficacy, reinforcing that tolerability driven adjustments are acceptable and often improve persistence on therapy. Slow dose escalation strategies may also reduce early adverse effects and lower discontinuation rates. Overall, consistent communication, flexible dosing, and coordinated follow up are key to sustaining safety and effectiveness throughout adjuvant or metastatic treatment courses.